159 related articles for article (PubMed ID: 16273996)
1. Deglycosylation of anti-beta amyloid antibodies inhibits microglia activation in BV-2 cellular model.
Rebe S; Solomon B
Am J Alzheimers Dis Other Demen; 2005; 20(5):303-13. PubMed ID: 16273996
[TBL] [Abstract][Full Text] [Related]
2. Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration.
Takata K; Hirata-Fukae C; Becker AG; Chishiro S; Gray AJ; Nishitomi K; Franz AH; Sakaguchi G; Kato A; Mattson MP; Laferla FM; Aisen PS; Kitamura Y; Matsuoka Y
Eur J Neurosci; 2007 Nov; 26(9):2458-68. PubMed ID: 17970733
[TBL] [Abstract][Full Text] [Related]
3. An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.
Adolfsson O; Pihlgren M; Toni N; Varisco Y; Buccarello AL; Antoniello K; Lohmann S; Piorkowska K; Gafner V; Atwal JK; Maloney J; Chen M; Gogineni A; Weimer RM; Mortensen DL; Friesenhahn M; Ho C; Paul R; Pfeifer A; Muhs A; Watts RJ
J Neurosci; 2012 Jul; 32(28):9677-89. PubMed ID: 22787053
[TBL] [Abstract][Full Text] [Related]
4. Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice.
Crehan H; Liu B; Kleinschmidt M; Rahfeld JU; Le KX; Caldarone BJ; Frost JL; Hettmann T; Hutter-Paier B; O'Nuallain B; Park MA; DiCarli MF; Lues I; Schilling S; Lemere CA
Alzheimers Res Ther; 2020 Jan; 12(1):12. PubMed ID: 31931873
[TBL] [Abstract][Full Text] [Related]
5. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.
Das P; Howard V; Loosbrock N; Dickson D; Murphy MP; Golde TE
J Neurosci; 2003 Sep; 23(24):8532-8. PubMed ID: 13679422
[TBL] [Abstract][Full Text] [Related]
6. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy.
Bacskai BJ; Kajdasz ST; McLellan ME; Games D; Seubert P; Schenk D; Hyman BT
J Neurosci; 2002 Sep; 22(18):7873-8. PubMed ID: 12223540
[TBL] [Abstract][Full Text] [Related]
7. Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide.
Lue LF; Walker DG
J Neurosci Res; 2002 Nov; 70(4):599-610. PubMed ID: 12404514
[TBL] [Abstract][Full Text] [Related]
8. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration.
Wilcock DM; Munireddy SK; Rosenthal A; Ugen KE; Gordon MN; Morgan D
Neurobiol Dis; 2004 Feb; 15(1):11-20. PubMed ID: 14751766
[TBL] [Abstract][Full Text] [Related]
9. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition.
Wilcock DM; Rojiani A; Rosenthal A; Levkowitz G; Subbarao S; Alamed J; Wilson D; Wilson N; Freeman MJ; Gordon MN; Morgan D
J Neurosci; 2004 Jul; 24(27):6144-51. PubMed ID: 15240806
[TBL] [Abstract][Full Text] [Related]
10. Antibody against C-terminal Abeta selectively elevates plasma Abeta.
Gray AJ; Sakaguchi G; Shiratori C; Becker AG; LaFrancois J; Aisen PS; Duff K; Matsuoka Y
Neuroreport; 2007 Feb; 18(3):293-6. PubMed ID: 17314674
[TBL] [Abstract][Full Text] [Related]
11. Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease.
Manczak M; Mao P; Nakamura K; Bebbington C; Park B; Reddy PH
Hum Mol Genet; 2009 Oct; 18(20):3876-93. PubMed ID: 19617638
[TBL] [Abstract][Full Text] [Related]
12. Analyzing microglial-associated Aβ in Alzheimer's disease transgenic mice with a novel mid-domain Aβ-antibody.
Henjum K; Årskog V; Jendresen CB; Fladby T; Torp R; Nilsson LNG
Sci Rep; 2020 Jun; 10(1):10590. PubMed ID: 32601313
[TBL] [Abstract][Full Text] [Related]
13. The role of microglia in antibody-mediated clearance of amyloid-beta from the brain.
Morgan D
CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):7-15. PubMed ID: 19275633
[TBL] [Abstract][Full Text] [Related]
14. Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies.
Fuller JP; Stavenhagen JB; Christensen S; Kartberg F; Glennie MJ; Teeling JL
Acta Neuropathol; 2015 Nov; 130(5):699-711. PubMed ID: 26433971
[TBL] [Abstract][Full Text] [Related]
15. IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease.
Browne TC; McQuillan K; McManus RM; O'Reilly JA; Mills KH; Lynch MA
J Immunol; 2013 Mar; 190(5):2241-51. PubMed ID: 23365075
[TBL] [Abstract][Full Text] [Related]
16. Cromolyn Reduces Levels of the Alzheimer's Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis.
Zhang C; Griciuc A; Hudry E; Wan Y; Quinti L; Ward J; Forte AM; Shen X; Ran C; Elmaleh DR; Tanzi RE
Sci Rep; 2018 Jan; 8(1):1144. PubMed ID: 29348604
[TBL] [Abstract][Full Text] [Related]
17. Maternal antibodies facilitate Amyloid-β clearance by activating Fc-receptor-Syk-mediated phagocytosis.
Illouz T; Nicola R; Ben-Shushan L; Madar R; Biragyn A; Okun E
Commun Biol; 2021 Mar; 4(1):329. PubMed ID: 33712740
[TBL] [Abstract][Full Text] [Related]
18. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
19. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice.
Koenigsknecht-Talboo J; Meyer-Luehmann M; Parsadanian M; Garcia-Alloza M; Finn MB; Hyman BT; Bacskai BJ; Holtzman DM
J Neurosci; 2008 Dec; 28(52):14156-64. PubMed ID: 19109498
[TBL] [Abstract][Full Text] [Related]
20. Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q.
Webster SD; Galvan MD; Ferran E; Garzon-Rodriguez W; Glabe CG; Tenner AJ
J Immunol; 2001 Jun; 166(12):7496-503. PubMed ID: 11390503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
